Skip to main content
Home
Zeitschriften
Zeitungen
Podcast
Gesundheitspolitik
Praxis
Allerlei
Jobs
Fachgebiete
Allgemeinmedizin Anästhesiologie & Intensivmedizin Apotheke Augenheilkunde Chirurgie Dermatologie Gynäkologie und Geburtshilfe HNO Innere Medizin Kinder & Jugendheilkunde Neurologie & Psychiatrie Orthopädie & Unfallchirurgie Pflege Urologie Zahnmedizin
Subfächer Innere Medizin
Diabetologie Gastroenterologie Infektiologie Kardiologie Onkologie und Hämatologie Pneumologie Rheumatologie
Fortbildungen
Überblick Fortbildungen DFP-Literaturstudium-Artikel DFP-Webcast Fortbildungen DFP-Podcasts
Erweiterte Suche
Anmelden
nach oben
memo - Magazine of European Medical Oncology
Erschienen in:

01.05.2024 | editorial

Antibody–drug conjugates (ADC special)—part 1

Approximation to the magic bullet

verfasst von: apl. Prof. Dr. Simon Peter Gampenrieder

Erschienen in: memo - Magazine of European Medical Oncology | Ausgabe 2/2024

Einloggen, um Zugang zu erhalten

Auszug

The third generation of antibody–drug conjugates (ADCs) constitute a real breakthrough with a rapid expansion of this innovative treatment approach in different tumor types, making ADCs one of the fastest-growing classes of drugs in oncology. Because ADCs combine the targeting capacity of monoclonal antibodies and the high efficacy of chemotherapeutic payloads, they are not only very effective anticancer treatments, but also less toxic than systemically administered chemotherapeutics. Currently, a total of 15 different ADCs are US Food and Drug Administration (FDA)-approved for different indications, mainly in the metastatic setting. …
Vorheriger Artikel Rare lung cancer special: a multifaceted approach
Nächster Artikel The future of clinical trials—goals, ideas, and discussion
Literatur
1.
2.
Metadaten
Titel
Antibody–drug conjugates (ADC special)—part 1
Approximation to the magic bullet
verfasst von
apl. Prof. Dr. Simon Peter Gampenrieder
Publikationsdatum
01.05.2024
Verlag
Springer Vienna
Erschienen in
memo - Magazine of European Medical Oncology / Ausgabe 2/2024
Print ISSN: 1865-5041
Elektronische ISSN: 1865-5076
DOI
https://doi.org/10.1007/s12254-024-00974-w

Weitere Artikel der Ausgabe 2/2024

Antibody–drug conjugates in ovarian cancer

  • Open Access
  • short review

Brief update on systemic therapies in myeloproliferative neoplasms

  • Open Access
  • short review

The future of clinical trials—goals, ideas, and discussion

  • Open Access
  • review

ASCO 2023: highlights in breast cancer

  • Open Access
  • short review

Upper-GI highlights from ASCO and ASCO-GI 2023 meetings: changing paradigm in treatment sequence

  • Open Access
  • short review

Congress update 2023—ASCO and ESMO

  • editorial